NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fluidigm Corporation FLDM, Stemline Therapeutics, Inc. STML, NeoGenomics, Inc. NEO, CVR Energy Inc. CVI, W.R. Berkley Corporation WRB, and Mack-Cali Realty Corporation CLI, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
FLDM DOWNLOAD: http://Fundamental-Markets.com/register/?so=FLDM
STML DOWNLOAD: http://Fundamental-Markets.com/register/?so=STML
NEO DOWNLOAD: http://Fundamental-Markets.com/register/?so=NEO
CVI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CVI
WRB DOWNLOAD: http://Fundamental-Markets.com/register/?so=WRB
CLI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLI
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Fluidigm Corporation FLDM, Stemline Therapeutics, Inc. STML, NeoGenomics, Inc. NEO, CVR Energy Inc. CVI, W.R. Berkley Corporation WRB, and Mack-Cali Realty Corporation CLI on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 5th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
FLUIDIGM CORPORATION (FLDM) REPORT OVERVIEW
Fluidigm's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Fluidigm reported revenue of $24.75MM vs $22.19MM (up 11.52%) and basic earnings per share -$0.46 vs -$0.68. Fluidigm is expected to report earnings on February 14th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.61. The estimated EPS forecast for the next fiscal year is -$0.70 and is expected to report on February 14th, 2018.
To read the full Fluidigm Corporation (FLDM) report, download it here: http://Fundamental-Markets.com/register/?so=FLDM
-----------------------------------------
STEMLINE THERAPEUTICS, INC. (STML) REPORT OVERVIEW
Stemline Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Stemline Therapeutics reported revenue of $0.30MM vs $0.30MM (unchanged) and basic earnings per share -$0.68 vs -$0.56. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Stemline Therapeutics reported revenue of $1.04MM vs $0.65MM (up 59.19%) and basic earnings per share -$2.15 vs -$2.15. Stemline Therapeutics is expected to report earnings on March 15th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.56. The estimated EPS forecast for the next fiscal year is -$1.80 and is expected to report on March 15th, 2018.
To read the full Stemline Therapeutics, Inc. (STML) report, download it here: http://Fundamental-Markets.com/register/?so=STML
-----------------------------------------
NEOGENOMICS, INC. (NEO) REPORT OVERVIEW
NeoGenomics' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, NeoGenomics reported revenue of $63.05MM vs $60.76MM (up 3.77%) and basic earnings per share -$0.10 vs -$0.07. For the twelve months ended December 31st, 2016 vs December 31st, 2015, NeoGenomics reported revenue of $244.08MM vs $99.80MM (up 144.57%) and basic earnings per share -$0.39 vs -$0.04. NeoGenomics is expected to report earnings on February 28th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.03. The estimated EPS forecast for the next fiscal year is $0.12 and is expected to report on February 28th, 2018.
To read the full NeoGenomics, Inc. (NEO) report, download it here: http://Fundamental-Markets.com/register/?so=NEO
-----------------------------------------
CVR ENERGY INC. (CVI) REPORT OVERVIEW
CVR Energy's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, CVR Energy reported revenue of $1,453.80MM vs $1,240.30MM (up 17.21%) and basic earnings per share $0.26 vs $0.06 (up 333.33%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, CVR Energy reported revenue of $4,782.40MM vs $5,432.50MM (down 11.97%) and basic earnings per share $0.28 vs $1.95 (down 85.64%). CVR Energy is expected to report earnings on February 15th, 2018. The report will be for the fiscal period ending December 31st, 2017.
To read the full CVR Energy Inc. (CVI) report, download it here: http://Fundamental-Markets.com/register/?so=CVI
-----------------------------------------
W.R. BERKLEY CORPORATION (WRB) REPORT OVERVIEW
W.R. Berkley's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, W.R. Berkley reported revenue of $2,031.34MM vs $2,019.73MM (up 0.58%) and basic earnings per share $1.29 vs $1.80 (down 28.33%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, W.R. Berkley reported revenue of $7,654.18MM vs $7,206.46MM (up 6.21%) and basic earnings per share $4.91 vs $4.06 (up 20.94%). W.R. Berkley is expected to report earnings on January 30th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.82. The estimated EPS forecast for the next fiscal year is $3.49 and is expected to report on January 30th, 2018.
To read the full W.R. Berkley Corporation (WRB) report, download it here: http://Fundamental-Markets.com/register/?so=WRB
-----------------------------------------
MACK-CALI REALTY CORPORATION (CLI) REPORT OVERVIEW
Mack-Cali Realty's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Mack-Cali Realty reported revenue of $160.02MM vs $157.52MM (up 1.59%) and basic earnings per share $0.39 vs -$0.10. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Mack-Cali Realty reported revenue of $613.40MM vs $594.88MM (up 3.11%) and basic earnings per share $1.31 vs -$1.41. Mack-Cali Realty is expected to report earnings on February 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.56. The estimated EPS forecast for the next fiscal year is $2.15 and is expected to report on February 27th, 2018.
To read the full Mack-Cali Realty Corporation (CLI) report, download it here: http://Fundamental-Markets.com/register/?so=CLI
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
